|
1st Sep 10 - NCPE review of the cost-effectiveness of certolizumab pegol (Cimzia®) for the treatment of moderate to severe rheumatoid arthritis. We do not recommend reimbursement of certolizumab pegol (Cimzia®) under the Community Drugs Schemes at the proposed price. download document |
|
15th Jul 10 - NCPE review of the cost-effectiveness of denosumab (Prolia®). We consider denosumab a cost-effective therapy for the prevention of osteoporotic fractures in postmenopausal women in the Irish heathcare setting. download document |
|
13th Jul 10 - New template for rapid review assessment submissions from manufacturers. Our new template for the rapid review process is to be found in the section "Pharmacoeconomic Guidelines". |
|
13th Jul 10 - NCPE review of the cost-effectiveness of oral oxycodone/naloxone prolonged release tablet (Targin®). We do not recommend reimbursement of oxycodone/naloxone (Targin®) under the Community Drugs Schemes at the proposed price. download document |
|
13th Jul 10 - Mifamurtide (Meptact®) for the treatment of osteosarcoma. A formal PEA is required to demonstrate value for money prior to reimbursement. |
|
22nd Jun 10 - Rapid review of Ofatumumab (Arzerra®) for the treatment of chronic lymphocytic leukaemia (CLL). We believe a formal PEA will be required to demonstrate value for money prior to reimbursement. |
|
2nd Jun 10 - NCPE review of the cost-effectiveness of golimumab (Simponi®) for the treatment of moderate to severe rheumatoid arthritis. Following a revision in price we consider golimumab a cost-effective option for the treatment of rheumatoid arthritis in the Irish Healthcare setting. download document |
|
11th May 10 - NCPE evaluation of the cost effectiveness of golimumab (Simponi®) for the treatment of moderate to severe rheumatoid arthritis. The reveiw group do not consider golimumab cost-effective at the submitted price. download document |
|
5th Mar 10 - Economic Evaluation of Eculizumab (Soliris®) for the treatment of paroxysmal noctural haemoglobinuria (PNH). Alexion Pharma UK. Ltd have failed to demonstrate the cost-effectiveness of eculizumab for the treatment of PNH in the Irish healthcare setting. download document |
|
1st Feb 10 - Economic Evaluation of Prasugrel (Efient®) for the prevention of atherothrombotic events in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention. The review group consider that prasugrel, co-administered with aspirin, is cost-effective in patients with acute coronary syndrome undergoing primary or delayed percutaneous coronary intervention in the Irish healthcare setting. download document |
|
15th Jan 10 - NCPE review of Indacaterol (Onbrez®) for the treatment of COPD It is recommended that Indacaterol (Onbrez®) should not be subjected to a PEA at this time. |
|
15th Jan 10 - NCPE evaluation of the cost-effectiveness of the rotavirus vaccine. NCPE completed the evaluation of the cost-effectiveness of a universal rotavirus vaccination programme in Ireland, on behalf of the National Immunisation Advisory Committee (NIAC). A summary of the main findings are available in the attached document: download document |
|
12th Jan 10 - NCPE Review of Dronedarone (Multaq®) for the treatment of current non-permanent atrial fibrillation. It is recommended that dronedarone should not under PEA at this time. |
|
11th Dec 09 - NCPE evaluation of agomelatine (Valdoxan®) for the treatment of major depressive disorder. Following a revision in price application we now consider agomelatine (Valdoxan®) cost effective under the Community Drugs schemes. The product will now be added to the list of items reimbursable under the schemes. |
|
8th Dec 09 - Cost effectiveness of Ustekinumab (Stelara®) for the treatment of moderate to severe plaque psoriasis. We consider ustekinumab cost effective for the treatment of moderate to severe plaque psoriasis in the Irish healthcare setting. download document |
|
8th Dec 09 - NCPE review of Adenuric (Febuxostat®) a xanthine oxidase inhibitor for the treatment of gout. It is recommended that Adenuric (Febuxostat®) should not be subjected to PEA at this time. |
|
19th Nov 09 - NCPE review of Ranolazine (Ranexa®) a late sodium channel inhibitor for the treatment of angina pectoris. We recommend that Ranolazine should not undergo PEA at this time. |
|
15th Oct 09 - NCPE Review of degarelix (Firmagon®) a GnRH antagonist for the treatment of prostate cancer. Following review it was recommended that degarelix should not be subjected to PEA at this time. |
|
7th Oct 09 - NCPE Review of Liraglutide (Victoza®) for the treatment of adults with type 2 diabetes mellitus. Following review it was recommended that Liraglutide should not be subjected to PEA at this time. |
|
3rd Sep 09 - NCPE evaluation of agomelatine (Valdoxan®) for the treatment of major depressive disorder. At the current price agomelatine (Valdoxan®) is not considered cost-effective for the treatment of major depressive episodes under the Community Drugs Schemes. download document |
|
18th Jun 09 - NCPE evaluation of sapropterin (Kuvan®) for the treatment of phenylketonuria (PKU). Sapropterin (Kuvan®) is not a cost effective treatment for patients with phenylketonuria. download document |
|
17th Jun 09 - Health technology assessment (HTA) of a population-based colorectal cancer screening programme in Ireland. This HTA was prepared by the National Cancer Registry Ireland, the National Centre for Pharmacoeconomics, the School for Health & Related Research, Sheffield University and Dublin City University. It is available on the HIQA website. Related Link |
|
16th Jun 09 - NCPE evaluation of the cost effectiveness of glucosamine sulfate (DONA®) for the treatment of osteoarthritis. We do not believe that glucosamine sulfate (DONA®) is a cost effective therapy for the treatment of osteoarthritis in the Irish Healthcare setting. download document |
|
2nd Jun 09 - NCPE evaluation of the impact of the post-patent price cut on medicines following the 2006 IPHA-HSE Agreement. Total savings on the GMS,DP and LTI schemes were estimated at €248.5 million. download document |
|
6th Feb 09 - NCPE reports on the cost-effectiveness of ambrisentan (Volibris®) in the treatment of patients with Functional Class II or III pulmonary arterial hypertension. A summary of the main findings are included in the attached document. download document |